𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Stefin B, the major low molecular weight inhibitor in ovarian carcinoma

✍ Scribed by Kastelic, L.; Turk, B.; Kopitar-Jerala, N.; Štolfa, A.; Rainer, S.; Turk, V.; Lah, T.T.

Book ID
122789014
Publisher
Elsevier Science
Year
1994
Tongue
English
Weight
719 KB
Volume
82
Category
Article
ISSN
0304-3835

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Progress in the design of low molecular
Progress in the design of low molecular weight thrombin inhibitors
✍ Stuti Srivastava; Lalit N. Goswami; Dinesh K. Dikshit 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 312 KB

Intravascular thrombosis and its complication, embolism, is a leading cause of morbidity and mortality throughout the world. Past few decades have seen a great deal of progress in the development of antithrombotic agents, though the current treatment options are limited to heparin, LMW heparins, and

Low-molecular weight forms of cyclin E d
Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma
✍ Ben Davidson; Martina Skrede; Ilvars Silins; Ie-Ming Shih; Claes G. Trope; Vivi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 232 KB 👁 1 views

## Abstract ## BACKGROUND. The authors recently reported on the role of cyclin E in differentiating ovarian/primary peritoneal carcinoma from malignant peritoneal mesothelioma using gene expression arrays. In the current study, they analyzed the expression of low‐molecular weight (LMW) forms of cy